ArticleJournal of cancer research and clinical oncology2012
In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.
Article in Journal of cancer research and clinical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Molecularly engineered tumor acidity-responsive plant toxin gelonin for safe and efficient cancer therapy.Bioactive materials · 2022Article
- Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivo.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies.Oncotarget · 2020Review
- Anti-CXCR4 Single-Chain Variable Fragment Antibodies Have Anti-Tumor Activity.Frontiers in oncology · 2020Article
- Expression and Evaluation of HuscFv Antibody -PE40 Immunotoxin for Target Therapy of EGFR-Overexpressing Cancers.Iranian journal of biotechnology · 2018Article
- Bouganin, an Attractive Weapon for Immunotoxins.Toxins · 2018Review
- Structural considerations for functional anti-EGFR × anti-CD3 bispecific diabodies in light of domain order and binding affinity.Oncotarget · 2018Article
- Anti-EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half-life.FEBS open bio · 2016Article
- Radionuclide therapy using ¹³¹I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression.Journal of cancer research and clinical oncology · 2016Article
- Autophagy in 5-Fluorouracil Therapy in Gastrointestinal Cancer: Trends and Challenges.Chinese medical journal · 2016Review
- Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.Oncogene · 2015Article
- Anti-tumor activities and apoptotic mechanism of ribosome-inactivating proteins.Chinese journal of cancer · 2015Review
- Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy.Journal of controlled release : official journal of the Controlled Release Society · 2014Article
- Magnetic targeting of novel heparinized iron oxide nanoparticles evaluated in a 9L-glioma mouse model.Pharmaceutical research · 2014Article
- Long-circulating heparin-functionalized magnetic nanoparticles for potential application as a protein drug delivery platform.Molecular pharmaceutics · 2013Article
- Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.Neoplasia (New York, N.Y.) · 2013Article
- Synergistic antitumor activity from two-stage delivery of targeted toxins and endosome-disrupting nanoparticles.Biomacromolecules · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEpidermal growth factor receptor (EGFR) plays an important role in the growth and metastasis of many solid tumors. Strategies that target EGFR hold promising therapeutic potential for the treatment for non-small cell lung cancer (NSCLC), as EGFR is normally overexpressed in these tumors. This study was designed to determine whether an anti-EGFR immunotoxin has anti-tumor activity against NSCLC, and if so, to further investigate the possible mechanisms of cytotoxicity.
methodsA fusion protein of anti-EGFR single-chain variable fragment (anti-EGFR scFv) and the plant toxin gelonin (rGel) was constructed, expressed in bacteria, and purified to homogeneity. Cytotoxicity of anti-EGFR scFv/rGel (E/rG) immunotoxin was assessed on A549, HCC827, and H1975 cells (EGFR-overexpressing NSCLC-derived cell lines) and A549 xenografts in nude mice.
resultsCytotoxicity experiments using E/rG on A549, HCC827, and H1975 cells demonstrated that E/rG can specifically inhibit proliferation of these cells, whereas it did not affect the proliferation of Raji cells that do not express EGFR. Treatment for A549 xenografts in nude mice with E/rG resulted in significant suppression of tumor growth compared to controls. Immunofluorescence in frozen tissue sections confirmed that E/rG could specifically bind to tumor tissues in nude mice bearing A549 tumor xenografts, while rGel alone showed no binding activity. Furthermore, E/rG inhibited the growth of A549 cells by cytotoxic effects that blocked tumor proliferation, and the immunotoxin-induced cell death may be mediated by autophagy.
conclusionsThese results showed that E/rG might have significant potential as a novel clinical therapeutic agent against human NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.